Novartis: Acromegaly trials

The registry lists 16 Acromegaly studies with Novartis as lead sponsor. 0 are open to participants now and 8 have results posted.

Phase 1 1Phase 2 3Phase 3 6Phase 4 5No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin AnaloguesCompletedNCT02354508Phase 3Results posted
• Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or AcromegalyCompletedNCT02060383Phase 4Results posted
• Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary GigantismCompletedNCT01673646Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic PatientsCompletedNCT01278342Phase 4Results posted
• Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled AcromegalyCompletedNCT01137682Phase 3Results posted
• Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active AcromegalyCompletedNCT00600886Phase 3Results posted
• Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled AcromegalyCompletedNCT00372697Phase 3Results posted
• An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With AcromegalyCompletedNCT00171730Phase 2Results posted
• An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With AcromegalyApproved for marketingNCT01995734
• Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid DiseaseCompletedNCT00446082Phase 1
• Efficacy of Octreotide Acetate and Cabergoline in Patients With AcromegalyCompletedNCT00376064Phase 4
• Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or MacroadenomasTerminatedNCT00242541Phase 4
• Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With AcromegalyCompletedNCT00225979Phase 3
• Octreotide Efficacy and Safety in First-line Acromegalic PatientsCompletedNCT00171886Phase 4
• Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic PatientsCompletedNCT00128232Phase 3
• Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic PatientsCompletedNCT00088582Phase 2